Enbrel (etanercept) / Pfizer, Amgen - LARVOL DELTA

Effect and safety of benzathine penicillin combined with Etanercept on spondyloarthritis: a multicenter randomized controlled clinical study (ChiCTR) - P=N/A | N=340 | Not yet recruiting | Sponsor: Nanfang Hospital, Southern Medical University; Nanfang Hospital, Southern Medical University

New trial • Ankylosing Spondylitis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis

Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta-Analysis. (PubMed, Pharmacotherapy) - "Alongside infliximab 5 mg/kg (SUCRA 98.6%), 10 mg/kg (92%), and 20 mg/kg intravenous (91.8%), the recently approved drugs guselkumab 1200 mg (83.2%), 600 mg (89.2%), and 200 mg intravenous (90.1%), as well as mirikizumab 600 mg (91.5%) and 1000 mg intravenous (82.4%) presented higher probabilities of disease remission and were associated with increased HRQoL. Drugs such as certolizumab, andecaliximab, fontolizumab, abatacept, and etanercept ranked low for remission (SUCRA < 40%) and presented high probabilities of serious adverse events (over 60%)...Given their safety profile, some anti-TNF drugs should be avoided in practice. Trial Registration: PROSPERO: CRD42024519150."

Journal • Retrospective data • Review • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "Our review shows that, compared to placebo, the biologics infliximab, xeligekimab, bimekizumab, ixekizumab, and risankizumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis, with high-certainty evidence for bimekizumab and moderate-certainty evidence for infliximab, xeligekimab, ixekizumab, and risankizumab. This network meta-analysis evidence is limited to induction therapy (outcomes measured from 8 to 24 weeks after randomisation), and is not sufficient for evaluating longer-term outcomes in this chronic disease. Moreover, we found low numbers of studies for some of the interventions, and the young age (mean 44.4 years) and high level of disease severity (PASI 20.5 at baseline) may not be typical of people seen in daily clinical practice. More randomised trials directly comparing active agents are needed, and these should include systematic subgroup analyses (sex, age, ethnicity, comorbidities, psoriatic arthritis)...."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Cystic Lung Disease in Patients With Psoriasis or Psoriatic Arthritis (CAP 2025) - "One patient received a 5-day course of steroids prior to biopsy, and another had a 15-year treatment history (etanercept/ixekizumab). Some patients with psoriasis/psoriatic arthritis may develop cystic lung disease radiologically and histologically consistent with lymphoid interstitial pneumonia."

Clinical • Dermatology • Fibrosis • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lymphoma • Pneumonia • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies

How treatment choices influence the onset and outcomes of uveitis ın juvenile idiopathic arthritis: a retrospective cohort study. (PubMed, Expert Opin Biol Ther) - "This patients were categorized based on their uveitis development: under methotrexate, after discontinuation of methotrexate, and under biologics...When the entire cohort of JIA patients treated with biologics for joint symptoms was evaluated, it was observed that out of 365 patients using etanercept, uveitis developed in 30 individuals, in one out of 39 patients using infliximab, while no cases of uveitis were observed among 285 patients using adalimumab...Monoclonal anti-TNF-α agents may remain the preferred options. This study highlights the necessity of integrating uveitis risk assessment into JIA treatment strategies."

Journal • Retrospective data • Idiopathic Arthritis • Immunology • Ocular Inflammation • Ophthalmology • Rheumatology • Uveitis

HSV PNEUMONIA IN PATIENT WITH PSORIATIC ARTHRITIS TAKING ETANERCEPT (CHEST 2025) - No abstract available

Clinical • Immunology • Infectious Disease • Inflammatory Arthritis • Pneumonia • Psoriatic Arthritis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies

AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS (Amgen Press Release) - "TEZSPIRE (tezepelumab-ekko) sales increased 46% year-over-year to $342 million in the second quarter, driven by volume growth. Otezla (apremilast) sales increased 14% year-over-year to $618 million in the second quarter, driven by 12% favorable changes to estimated sales deductions and 4% volume growth. Enbrel (etanercept) sales decreased 34% year-over-year to $604 million in the second quarter, driven by 20% unfavorable changes to estimated sales deductions and 19% lower net selling price resulting from increased 340B Program mix and the impact of the U.S. Medicare Part D redesign, partially offset by 3% volume growth."

Sales • Asthma • Dermatology • Immunology • Psoriatic Arthritis • Rheumatoid Arthritis

The Efficacy and Safety of Tumor Necrosis Factor alpha Inhibitors in the Treatment of Noninfectious Uveitis: A Systematic Review and Meta-Analysis. (PubMed, J Ocul Pharmacol Ther) - " This meta-analysis demonstrates that TNF-α inhibitors significantly improve inflammation, VA, and reduce CMT and CS use in NIU. While adalimumab and infliximab exhibit comparable efficacy, infliximab is associated with a higher adverse event rate, highlighting the need for personalized treatment."

Journal • Retrospective data • Ocular Inflammation • Oncology • Ophthalmology • Uveitis

The case for etanercept in the management of toxic epidermal necrolysis. (PubMed, Skin Health Dis) - "Patients with TEN have prominent expression of TNF-α in keratinocytes and macrophages in affected skin as well as in blister fluid. This review article aims to summarize the recent and emerging evidence for using anti-TNF-α treatment, particularly etanercept, in the management of TEN."

Journal • Review • Oncology • Steven-Johnson Syndrome

Etanercept and topical Silver Nitrate in Stevens Johnson Syndrome: a pilot study. (EADV 2025) - No abstract available

Clinical • Steven-Johnson Syndrome

Acute Lymphoblastic Leukemia Following Etanercept Therapy in a Patient with Psoriasis (EADV 2025) - No abstract available

Clinical • Acute Lymphocytic Leukemia • Dermatology • Hematological Malignancies • Immunology • Leukemia • Oncology • Psoriasis

Prescribing pattern of disease-modifying antirheumatic drugs in Scotland (2019-2023): a population-based retrospective cohort study. (PubMed, Expert Rev Clin Pharmacol) - "Adalimumab and etanercept were the predominant agents. This is the first national study to characterize real-world DMARD prescribing in Scotland using comprehensive homecare data. Findings provide critical benchmarks for therapeutic optimization, inform guideline development, and support sustainable planning for high-cost medicines delivery in rheumatology."

Journal • Retrospective data • Ankylosing Spondylitis • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Mevalonate kinase deficiency: genetic and clinical characteristics of a Chinese pediatric cohort. (PubMed, Pediatr Rheumatol Online J) - "This study is the largest case series of MKD pediatric patients from China. Four new mutation sites in MVK were identified, further expanding the phenotypic and genotypic spectrum of MKD and emphasizing the significance of MVK mutation patterns in influencing disease severity."

Journal • Developmental Disorders • Hematological Disorders • Inflammation • Pediatrics

Three-year outcomes of tumor necrosis factor alpha inhibitor therapy in rheumatoid arthritis patients with elevated liver enzymes. (PubMed, World J Hepatol) - "TNFi therapy (adalimumab or etanercept) was associated with significant improvement in liver enzymes and FIB-4 without hepatic decompensation, supporting its safety in our cohort of RA patients with liver involvement. Larger prospective studies are warranted to further validate these findings."

Journal • Fibrosis • Immunology • Inflammatory Arthritis • Liver Failure • Oncology • Rheumatoid Arthritis • Rheumatology

Treatment sequences in moderate-to-severe psoriasis: a hospital-based retrospective analysis. (PubMed, Expert Opin Biol Ther) - "Adalimumab was the most common first-line biologic (27%), followed by secukinumab (18%) and etanercept (16%). After adjusting for confounding variables, ustekinumab maintained its positive effect on treatment duration (β = 0.285, p = 0.009). The treatment duration for ustekinumab was encouraging, supporting its potential role as a durable option in these patients."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis

Five-Year Experience of Etanercept as Adjunct to Intravenous Immunoglobulin for Kawasaki Disease with Coronary Artery Involvement. (PubMed, J Pediatr Clin Pract) - "Etanercept as intensification therapy for KD with coronary artery aneurysms can be delivered safely and with good compliance. This report suggests benefit in preventing long-term persistence of severe and any coronary artery disease."

Journal • Cardiovascular • Coronary Artery Disease • Vasculitis

Evaluation of Optimal Engraftment Sites for Human Stem Cell-Derived Islets in a Non-Human Primate Model (WTC 2025) - "The immunosuppressive regimen consisting of Thymo, Rituxan, and Enbrel for induction, with maintenance involving Belatacept, anti-CD40L, Rapamycin, and FK506. A notable initial graft loss was observed, as anticipated for primary islet transplantation, ranging from 60% to 98% among transplant sites. This study marks the first report of utilizing a single batch of SC-islets and simultaneously transplanting SC-islets into six sites of one recipient, aiming to eliminate batch and recipient variations. The omentum, a top-performing site, offers high initial graft survival and many advantages over the current favored intrahepatic approach, particularly graft retrievability in teratoma or tumor cases."

Preclinical • CD40LG

Management of Graft versus Host Disease Involving the Bone Marrow: Interventions and Outcomes (WTC 2025) - "87.5% of them also received Etanercept as part of the treatment regimen, and half of them also received Photopheresis... GVHD after solid organ transplantation typically presents with rash, diarrhea, fever, and pancytopenia 2 to 8 weeks after transplantation. Cytopenia has been described to confer a worse outcome. The lack of clinical trials for GVHD treatment limits an effective therapeutic strategy, and treatment outcomes of GVHD post liver transplant tend to be poor, with >85% mortality rate."

Acute Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Solid Organ Transplantation

Update on Biologic Therapy in Juvenile Idiopathic Arthritis: A Five-year Narrative Review. (PubMed, Biologics) - "The "biologic era" in the management of juvenile idiopathic arthritis (JIA) has begun in the year 2000, with the publication of the randomized controlled trial on etanercept...The research agenda also calls for the search for reliable early predictors of therapeutic response that foster personalization of treatment and increase its precision. The aim of this Review is to summarize the evidence obtained in the past 5 years in the field of biologic therapy for JIA and to discuss the remaining gaps and the future perspectives of the use of these medications."

Journal • Review • Idiopathic Arthritis • Immunology • Pediatrics • Rheumatology

Trend in the use of biological drugs in pediatric patients with immune-mediated inflammatory diseases: insight from the large-scale Italian VALORE project. (PubMed, Pharmacol Res) - "Among incident users, persistence to adalimumab, etanercept, infliximab, golimumab, tocilizumab, secukinumab, and abatacept was measured. After one year from the treatment start, more than 70% of JIA patients using either adalimumab or etanercept were still on treatment, while persistence rates in IBDs were lower (ranging from 57.4% to 65.0%). Findings of this study show the potential of the VALORE network to provide enough exposure data to investigate the risk of serious infections for adalimumab, etanercept, and infliximab."

Journal • Gastroenterology • Gastrointestinal Disorder • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pediatrics • Rheumatology

TNF-α-NF-κB activation through pathological α-Synuclein disrupts the BBB and exacerbates axonopathy. (PubMed, Cell Rep) - "Further in vivo studies with PFF induced α-synucleinopathy, and a transgenic animal model (G2-3) revealed that α-Syn aggregation disrupts the BBB, leading to axonal degeneration that was mitigated by treatment with a non-BBB-penetrating TNF-α inhibitor, etanercept. These findings suggest that targeting brain endothelial TNF-α signaling could be a potential therapeutic approach for synucleinopathy-related NDs."

Journal • CNS Disorders • TNFA

Epidural Steroid Injection as a Treatment Alternative for Ankylosing Spondylitis Complicated by Andersson Lesions: A Case Report (PAINWeek 2025) - "In one and a half year, fluoroscopy-guided erector spinae blocks at T7-T8 with ropivacaine and Kenalog provided 60% relief...The patient was switched to adalimumab, and a left paramedian T6-7 epidural steroid injection provided 90% pain relief... We present a 59-year-old male with a history of hypertension, anxiety, depression, peripheral axonal neuropathy, and longstanding ankylosing spondylitis who presented to the pain clinic with significant mid-thoracic, lumbar, and sacral pain worsening for the past 10 years. Despite initiating anti-tumor necrosis factor (TNF) therapy with etanercept for ankylosing spondylitis one year prior and conservative management with physiotherapy and opioids, he continued to experience persistent but controlled thoracic pain, managed electively only with celecoxib. Sacral and lumbar pain were treated with sacroiliac joint injections and medial branch blocks, respectively, with good result."

Case report • Clinical • CNS Disorders • Depression • Pain • Psychiatry

High rheumatoid factor does not diminish efficacy of TNF inhibitors in seropositive JIA. (PubMed, Pediatr Rheumatol Online J) - "Unlike in adults, efficacy of TNFi was not diminished by elevated levels of RF in this cohort of pediatric patients with seropositive polyarthritis. Further studies are necessary to confirm these findings."

Journal • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Pediatrics • Rheumatology

Frequency of tuberculosis in psoriasis patients using anti-TNF therapy during 16 years of follow-up. (PubMed, Postepy Dermatol Alergol) - "Anti-tumor necrosis factor (TNF) agents such as adalimumab, infliximab, etanercept are effectively used for treatment. The common feature of these patients was a history of etanercept treatment. We concluded that psoriasis patients receiving TNF inhibitor therapy are at risk of tuberculosis infection despite isoniazid prophylaxis and contrary to the literature it looks like those patients treated with etanercept may be at greater risk for tuberculosis than patients treated with other TNF inhibitor agents."

Journal • Dermatology • Immunology • Infectious Disease • Oncology • Psoriasis • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Quantifying the Role of Specialty Medications in Medicare Part D Expenditures in Dermatology. (PubMed, JAMA Dermatol) - "New therapies approved after 2013 (Otezla, Cosentyx, Taltz, Dupixent, Tremfya, Skyrizi, and Odomzo) accounted for 69.5% of all spending growth. Prescription rates increased more slowly for older specialty drugs (Humira, Enbrel, Stelara, and Erivedge), but their prices increased more (9.2% annually) than prices for newer agents...While the price of the average dermatologic medication has increased rapidly, this primarily reflects increased prescribing of newly introduced specialty drugs. While these therapies expand treatment options, their rising share of costs highlights the need for policies that balance innovation, access, and affordability."

Journal • Medicare • Reimbursement • US reimbursement • Dermatology